KRAS and cancer: TG01 (Targovax ASA, Oslo, Norway) is the first injectable antigen-specific cancer immunotherapy (ASCI) targeted to treat patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations.10 TG01 consists of a mixture of 7 synthetic RAS peptides representing the 7 most common codon 12 and 13 oncogenic mutations in KRAS.